Genzyme Proposes To "Disentangle" Schering From Campath Marketing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposal is an effort to win FTC approval for Genzyme's $1 bil. bid for Ilex. Genzyme expects to issue 22 mil. shares as part of the deal, but the dilution may be offset by stronger than previously expected performance of Renagel, Fabrazyme and Cerezyme.
You may also be interested in...
Genzyme Eyeing Fourth Quarter Close For Ilex Merger
Genzyme expects its proposed merger with Ilex to close in the fourth quarter, Genzyme CEO Henri Termeer said
Genzyme Eyeing Fourth Quarter Close For Ilex Merger
Genzyme expects its proposed merger with Ilex to close in the fourth quarter, Genzyme CEO Henri Termeer said
Thymoglobulin Capping Defects Cited In Aventis Pasteur Warning Letter
FDA cites Genzyme’s Thymoglobulin contract manufacturer Aventis Pasteur for failures related to its quality control unit. Warning letter also points to quality control deficiencies involving haemophilius b conjugate vaccine and rabies vaccine.